# Phase 2 breast cancer trials recruiting: 532 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 532 trials in phase 2 for breast cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 breast cancer trials: 532 rows for $26.60, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 12 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/breast-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 532
- Recruiting or not yet: 532
- Read on: November 19, 2026

## Trials

The 25 newest of 532, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07937605 | KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer | Beijing Konruns Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937605) |
| November 13, 2026 | NCT07935317 | A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer | Eli Lilly and Company | Phase 2 | Not yet recruiting | Breast Neoplasms | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935317) |
| November 13, 2026 | NCT07935226 | Induction Trastuzumab Rezetecan Followed by Maintenance Dalpiciclib and Endocrine Therapy as First-line Treatment of HR+/HER2 Low mBC | Harbin Medical University | Phase 2 | Not yet recruiting | Breast Cancer (Locally Advanced or Metastatic), HR Positive/HER2 Low Breast Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935226) |
| November 5, 2026 | NCT07918989 | A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation Therapy After... | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Breast Cancer, Breast Cancer Female | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918989) |
| November 5, 2026 | NCT07918079 | Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy | Fudan University | Phase 2 | Not yet recruiting | Breast Cancer | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918079) |
| November 3, 2026 | NCT07914309 | Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer | Washington University School of Medicine | Phase 2 | Not yet recruiting | Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC), Breast Cancer | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914309) |
| November 2, 2026 | NCT07909889 | Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer | Aarhus University Hospital | Phase 2 | Not yet recruiting | Breast Cancer (Early Breast Cancer), Obesity | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909889) |
| November 2, 2026 | NCT07909408 | Psilocybin FCR Early-Stage Breast Cancer | NYU Langone Health | Phase 2 | Not yet recruiting | Early-stage Breast Cancer, Fear of Cancer Recurrence, Anxiety, Depression | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909408) |
| October 30, 2026 | NCT07907354 | Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer | Yunnan Cancer Hospital | Phase 2 | Not yet recruiting | Breast Neoplasms, Advanced Breast Cancer, HER2-positive Breast Cancer, HER2-low Breast Cancer | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907354) |
| October 29, 2026 | NCT07905313 | Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and... | Azienda Ospedaliero-Universitaria Careggi | Phase 2 | Not yet recruiting | Breast Cancer (Advanced/Metastatic) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905313) |
| October 28, 2026 | NCT07900516 | A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant... | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Breast Cancer | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900516) |
| October 27, 2026 | NCT07896668 | Pucotenlimab and Anlotinib in Combination With Chemotherapy | Zhejiang Cancer Hospital | Phase 2 | Recruiting | Breast Cancer | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896668) |
| October 26, 2026 | NCT07893730 | Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches | University College Cork | Phase 2 | Not yet recruiting | Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893730) |
| October 22, 2026 | NCT07889115 | Evaluation of the Effect of Amantadine in the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients | Al-Azhar University | Phase 2 | Not yet recruiting | Breast Cancer, Peripheral Neuropathy Due to Chemotherapy, VAS Score | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889115) |
| October 20, 2026 | NCT07884201 | Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment | Fudan University | Phase 2 | Not yet recruiting | Breast Cancer, TNBC - Triple-Negative Breast Cancer, Immunotherapy | 572 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884201) |
| October 20, 2026 | NCT07883512 | EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction) | Virginia Commonwealth University | Phase 2 | Not yet recruiting | Breast Cancer, Supportive Care in Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883512) |
| October 15, 2026 | NCT07876557 | A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative... | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 | Recruiting | Triple-negative Breast Cancer | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876557) |
| October 7, 2026 | NCT07862751 | US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving... | Emory University | Phase 2 | Not yet recruiting | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862751) |
| October 5, 2026 | NCT07857486 | Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer | Institut Paoli-Calmettes | Phase 2 | Not yet recruiting | Early Triple-Negative Breast Cancer | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857486) |
| October 5, 2026 | NCT07857226 | Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer | Hebei Medical University Fourth Hospital | Phase 2 | Not yet recruiting | Breast Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857226) |
| October 2, 2026 | NCT07856303 | SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response | Fudan University | Phase 2 | Not yet recruiting | HER2-positive Breast Cancer, Early Breast Cancer (EBC) | 358 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856303) |
| September 30, 2026 | NCT07848984 | Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in... | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Not yet recruiting | Breast Neoplasms | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848984) |
| September 29, 2026 | NCT07848243 | Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes | Peking University Cancer Hospital & Institute | Phase 2 | Recruiting | Lung Cancer (NSCLC), Cervical Squamous Cell Cancer, Melanoma (Skin Cancer), Breast Cancer, Gastrointestinal Cancers | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848243) |
| September 28, 2026 | NCT07844018 | ADC Based Therapy Accroding to HER2 Heterogeneous | Peking University People's Hospital | Phase 2 | Not yet recruiting | Breast Cancer (Early Breast Cancer) | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844018) |
| September 23, 2026 | NCT07836257 | A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd | Fujian Medical University | Phase 2 | Not yet recruiting | Breast Cancer | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836257) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 43 |
| Henan Cancer Hospital | 14 |
| Memorial Sloan Kettering Cancer Center | 14 |
| Tianjin Medical University Cancer Institute and Hospital | 13 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 12 |
| Sun Yat-sen University | 11 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 10 |
| UNC Lineberger Comprehensive Cancer Center | 8 |
| UNICANCER | 8 |
| The First Affiliated Hospital with Nanjing Medical University | 8 |
| Dana-Farber Cancer Institute | 7 |
| H. Lee Moffitt Cancer Center and Research Institute | 7 |
| Hebei Medical University Fourth Hospital | 7 |
| Shengjing Hospital | 7 |
| City of Hope Medical Center | 6 |
| National Cancer Institute (NCI) | 6 |
| First Affiliated Hospital of Zhejiang University | 6 |
| M.D. Anderson Cancer Center | 6 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 5 |
| Mayo Clinic | 5 |
| Shanghai Jiao Tong University School of Medicine | 5 |
| Fujian Cancer Hospital | 5 |
| Washington University School of Medicine | 5 |
| University of Wisconsin, Madison | 4 |
| Zhejiang Cancer Hospital | 4 |

## By country

| Country | Trials |
| --- | --- |
| China | 182 |
| United States | 176 |
| France | 23 |
| Spain | 19 |
| Canada | 18 |
| Italy | 17 |
| South Korea | 12 |
| Germany | 12 |
| United Kingdom | 9 |
| Japan | 9 |
| Belgium | 8 |
| Taiwan | 8 |
| Netherlands | 7 |
| Brazil | 6 |
| Australia | 5 |
| Sweden | 4 |
| Argentina | 4 |
| Denmark | 4 |
| Poland | 3 |
| Mexico | 3 |
| Nigeria | 3 |
| Switzerland | 3 |
| Norway | 3 |
| Egypt | 3 |
| Russia | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Medical testing laboratories in the United States](https://specstream.ai/data/businesses/medical-testing-laboratories/united-states)
- [Wind energy companies in the United States](https://specstream.ai/data/businesses/wind-energy-companies/united-states)
- [Fastener suppliers in the United States](https://specstream.ai/data/businesses/fastener-suppliers/united-states)
- [Propane suppliers in the United States](https://specstream.ai/data/businesses/propane-suppliers/united-states)
- [Billing services in the United States](https://specstream.ai/data/businesses/billing-services/united-states)
- [Investment management firms in the United States](https://specstream.ai/data/businesses/investment-management-firms/united-states)
